Notably, our findings demonstrated that FTO expression was related to an unfavorable outcome in GC, while increased MOXD1 expression was significantly associated with a poorer prognosis in the GC cohort (Fig. 6). The gene discussed is MOXD1; the disease is gastric cancer.